Events

Mass Bio State of Possible Conference w/ Rachel Hodos

AI and Drug Discovery: Marrying Data Science with Core Biology"

In Summary: Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating 'wet' in vitro/in vivo and 'dry' insilico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This panel will explore the new world of AI and Drug Discovery as a way to model potential drug effects more accurately and quickly.

→ Event Website


Rachel Hodos
Senior AI Scientist at BenevolentAI

Rachel has been with BenevolentAI for almost 2 years where she currently leads the application of AI to Target Identification. She has a PhD in Computational Biology from NYU applying machine learning to transcriptomic data for drug discovery applications, and a B.S. in Mathematics from the University of Houston. She also worked for 2 years as a software engineer at NASA’s Jet Propulsion Laboratory in Pasadena, California.

More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021